These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 728326)

  • 41. [Updating haloperidol: 1975].
    Ayd FJ
    Acta Physiol Lat Am; 1978 Sep; 24(3):233-8. PubMed ID: 751446
    [No Abstract]   [Full Text] [Related]  

  • 42. [Clinical psychometric evaluation of the effects of fluanxol, oxipertine and chlorpromazine in chronic schizophrenia. Comparative study].
    Predescu V; Ciurezu T; Romila A; Pirée S; Vianu I; Ionescu G; Braslă N; Florescu D; David E; Roman I; Zelingher R; Ivana D; Bucurică C; Damian N
    Neurol Psihiatr Neurochir; 1969; 14(5):389-400. PubMed ID: 5380156
    [No Abstract]   [Full Text] [Related]  

  • 43. MAO activity, serotonin metabolism and aggregation of platelets from migraine patients. A preliminary study.
    Kovács K; Tóthfalusi L; Hermán F; Magyar K
    Pol J Pharmacol Pharm; 1988; 40(6):691-5. PubMed ID: 3152004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia.
    Morton MR
    Am J Psychiatry; 1968 May; 124(11):1585-8. PubMed ID: 4869439
    [No Abstract]   [Full Text] [Related]  

  • 45. [Changes in erythrocyte shape in children treated with chlorpromazine].
    Bichoński R; Tabarowski Z; Dabrowski Z
    Folia Med Cracov; 1992; 33(1-4):59-64. PubMed ID: 1343002
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma-level studies of chlorpromazine following the administration of chlorpromazine hydrochloride and chlorpromazine embonate in chronic schizophrenics.
    Cooper SF; Albert JM; Hillel J; Caille G
    Curr Ther Res Clin Exp; 1973 Feb; 15(2):73-7. PubMed ID: 4632509
    [No Abstract]   [Full Text] [Related]  

  • 47. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
    Glusa E; Markwardt F
    Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. On the possible role of enzyme induction in cases of resistancy to chlorpromazine treatment.
    Arató M; Varadi A
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):296-8. PubMed ID: 616930
    [No Abstract]   [Full Text] [Related]  

  • 49. Methodological issues in psychopharmacological research.
    Davis JM; Hurt SW
    Am J Orthopsychiatry; 1977 Jul; 47(3):523-36. PubMed ID: 888926
    [No Abstract]   [Full Text] [Related]  

  • 50. Loxapine: a double-blind comparison with chlorpromazine in acute schizophrenic patients.
    Steinbook RM; Goldstein BJ; Brauzer B; Moreno SS; Jacobson AF
    Curr Ther Res Clin Exp; 1973 Jan; 15(1):1-7. PubMed ID: 4631378
    [No Abstract]   [Full Text] [Related]  

  • 51. Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships.
    Clark ML; Ramsey HR; Rahhal DK; Serafetinides EA; Wood FD; Costiloe JP
    Arch Gen Psychiatry; 1972 Oct; 27(4):479-83. PubMed ID: 5072717
    [No Abstract]   [Full Text] [Related]  

  • 52. The effect of chlorpromazine on plasma renin activity and aldosterone in man.
    Robertson D; Michelakis AM
    J Clin Endocrinol Metab; 1975 Dec; 41(06):1166-8. PubMed ID: 1206100
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine antagonism by thioridazine in schizophrenia.
    Meltzer HY; Sachar EJ; Frantz AG
    Biol Psychiatry; 1975 Feb; 10(1):53-7. PubMed ID: 1120175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison of the relative efficacy of Serenace and chlorpromazine in the treatment of chronic schizophrenics.
    Rompel H; Segal H
    J Int Med Res; 1978; 6(2):126-32. PubMed ID: 344086
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasma cyclic AMP in schizophrenics.
    Lykouras E; Varsou E; Rinieris P; Stefanis CN
    Prog Neuropsychopharmacol; 1980; 4(1):69-74. PubMed ID: 6250180
    [No Abstract]   [Full Text] [Related]  

  • 56. [Effect of thioridazine and chlorpromazine on the ECG and serum potassium level--ECG of the glucose load in 40 cases].
    Kuang RY
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1988 Oct; 21(5):297-9, 319. PubMed ID: 3234162
    [No Abstract]   [Full Text] [Related]  

  • 57. Effect of chlorpromazine on the cell metabolism.
    YAMAMOTO I; TSUJIMOTO A; TSUJIMURA Y; MINAMI M; KUROGOCHI Y
    Jpn J Pharmacol; 1957 Mar; 6(2):138-46. PubMed ID: 13480753
    [No Abstract]   [Full Text] [Related]  

  • 58. Mechanism of oxidative phosphorylation.
    DAWKINS MJ; JUDAH JD; REES KR
    Nature; 1958 Sep; 182(4639):875-6. PubMed ID: 13590150
    [No Abstract]   [Full Text] [Related]  

  • 59. Antipsychotic-induced venous thromboembolism: a review of the evidence.
    Hägg S; Spigset O
    CNS Drugs; 2002; 16(11):765-76. PubMed ID: 12383032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.
    Youdim MB; Hefez A; Oppenheim B
    Br J Clin Pharmacol; 1981 Oct; 12(4):535-42. PubMed ID: 7295487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.